Simeprevir receives positive CHMP opinion for the treatment

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 21, 2014 at 11:00 AM

Simeprevir receives positive CHMP opinion for the treatment of adults with chronic hepatitis C in the European Union

· Positive opinion for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients. Stockholm, Sweden — Medivir AB (OMX: MVIR) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients. “The recommendation is one additional step in the global strategy that our partner Janssen has for simeprevir, to offer a new and efficacious treatment option to the many hepatitis C patient groups suffering from this devastating disease” said Maris Hartmanis CEO, Medivir. Simeprevir is a new generation, NS3/4A protease inhibitor administered as a once daily 150 mg capsule with pegylated interferon (PegIFN) and ribavirin (RBV) offering proven efficacy across a range of different HCV patient types. The CHMP opinion was based on positive and consistent results from three pivotal phase III studies in patients with GT1 HCV; QUEST-1 and QUEST-2 in treatment -naïve patients and PROMISE in patients (who have relapsed after previous interferon-based therapy). QUEST-1 and QUEST-2 included 785 treatment-naïve patients with chronic HCV GT1 infection. PROMISE included 393 relapsed patients with chronic HCV GT1 infection. All three studies met their primary end points and demonstrated simeprevir in combination with PegIFN/RBV achieves superior cure rates when compared with PegIFN/RBV alone, in treatment naïve and relapsed patients. Hepatitis C in the European Union Hepatitis C is a major health problem in the European Union, where nine million people are living with the disease. The current standard of care is not always tolerable due to significant side effects of interferon based therapy and improvements in efficacy for difficult to treat patients, such as prior null responders, represent a high medical need. Treatment of HCV is complex because of the heterogeneous population of patients it affects and that treatment efficacy is highly dependent on the genotype of the virus. For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 15.45 CET on 21 March 2014. About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB will retain marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of genotype 1 hepatitis C in September 2013 in Japan and in November 2013 in Canada and the U.S. About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics. For more information about Medivir AB, please visit the Company’s website: www.medivir.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DIR Launches ManhattanHockey.com Amid Rangers' 100th Year

Digital Information Makes a Bold Play in Sports Media The puck drops in a whole new way today as Digital Information Resources (DIR) decides it's the digital age for hockey. They've tossed their hat into the rink, launching ManhattanHockey.com, wholeheartedly dedicated to fans of the New York Rangers. The timing's no fluke—this year marks the century milestone for the...

AAN Seeks Donations to Drive Crucial Brain Research

Boosting Brain Horizons: The Need for Donations Urgency clings to the air like smoke around a campfire when it comes to funding brain research. The American Academy of Neurology (AAN) knows this, and they've kicked off their year-end giving campaign, trying to rope in every penny they can muster for the AAN Research Program. With brain diseases lining up like unwanted...

NetEase Awaits Q3 2026 Results: What's at Stake?

D-Day for NetEase: Quarterly Results Incoming We're inching closer to November 19, 2026, and if you hold a piece of NetEase (NASDAQ: NTES), you're probably on pins and needles. This is when the curtains rise on their third-quarter financial results, which they've been fiercely guarding like a high-stakes poker hand. They'll be laying it all out right before the U.S....

Sysco's Regulatory Hurdle: Investors Eye Jetro Deal Risks

Sysco's Tumultuous Day: A Sharp Dive Well, folks, if you're holding onto Sysco shares, you might be feeling the pinch. On November 3, 2026, Sysco Corporation (NYSE: SYY) took a nosedive, dropping 9.3% in a single trading session. The reason? A hefty $29.1 billion acquisition deal that's still caught up in regulatory limbo. The looming merger with Jetro Restaurant Depot...

Sharon Bowen Honored; e.l.f. Beauty Hits 31 Quarters

Markets Stir as NYSE Chair Earns Lifetime Award While the financial world often gets lost in numbers, sometimes it's the people who stand out. NYSE Chair Sharon Bowen is taking the spotlight with her lifetime achievement award, underscoring her game-changing influence in governance. This is more than just a pat on the back; it's a nod to the force she’s been in steering...

Preplanning Funerals: Choices for Clarity and Comfort

Making Clear Plans for the Inevitable Man, if life is certain about one thing, it’s the endgame. And nobody wants to pass the buck on sorting out the details when they’re six feet under. Enter funeral preplanning – a chance to write the script for your own final episode and keep your family out of the weeds when the time comes. Jake Leonetti over at Stone Chapel...

Ryde Group Faces Fraud Claims: Investor Action Looms

Big Trouble in the Stock Market for Ryde Group Well, hold onto your hats, folks—Ryde Group Ltd. is neck-deep in legal hot water. If you thought the stock market was a place of pure strategy and devoid of any drama, think again. Recently, DJS Law Group threw down the gauntlet with a class action lawsuit against Ryde Group (NYSE American: RYDE) for some pretty hefty...

Hidden Costs of Lineworker and CDL Training in California

The True Financial Picture of Skilled Trade Programs Ever wonder why that flashy tuition number doesn't line up with your wallet by the end of your training days? That's the reality smashing aspiring lineworkers and future truck drivers in Northern California right in the face. We're talking about a full breakdown here, beyond what the glossy brochures ever tell you....

Manulife's Q3 2026: Strong Gains Amid Income Dip

Manulife's Resilience in a Volatile Market Trading has a way of keeping folks on their toes. Just when you think you've ridden the bull long enough, it tries bucking you off. That's how it goes for Manulife Financial Corporation (TSX/NYSE/PSE: MFC), as they reported their Q3 2026 results—marking a seesaw of gains and losses. Core Earnings Shine While Net Income Declines...

Bram Schot Steers Marelli Through Chapter 11 Resurgence

So, Marelli's rolling out the heavy artillery with the appointment of Bram Schot as their future Chair. This isn't just reshuffling a few chairs on the deck of a wobbly ship. No, Marelli's emergence from Chapter 11, with Schot at the helm, is more akin to a full-blown course correction. The man comes seasoned, having braved the corporate gales at Audi, Mercedes-Benz, and...